Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Whole transcriptome gene expression in Alzheimer's disease (AD) patients [lncRNA]

ABSTRACT: Alzheimer disease (AD) is the most common type of dementia. It is a progressive disease initially characterized by memory loss and leading to loss of the ability to respond to the environment. Currently, there is no single molecular or imaging test that can establish an AD diagnosis. A clinical diagnosis is often the results of multiple cognitive tests, spinal fluid or other bodily fluid tests for specific biomarkers and brain imaging, and it is often a diagnosis of exclusion for other diseases. We utilized a whole transcriptome sequencing approach to analyze gene expression in AD patients and control subjects blood samples with the goal of developing a novel panel of biomarkers for the disease. Whole blood sample were collected from 50 AD patients and 50 matched controls. AD patients were defined by a clinical diagnosis supported by 3 cognitive tests (MMSE, ADAS, CDR). Healthy donors have an unremarkable clinical history and their scores in the 3 cognitive tests are within normal ranges.

ORGANISM(S): Homo sapiens

PROVIDER: GSE248417 | GEO | 2026/03/11

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Whole transcriptome gene expression in Alzheimer's disease (AD) patients [sRNA]

Project description:Alzheimer disease (AD) is the most common type of dementia. It is a progressive disease initially characterized by memory loss and leading to loss of the ability to respond to the environment. Currently, there is no single molecular or imaging test that can establish an AD diagnosis. A clinical diagnosis is often the results of multiple cognitive tests, spinal fluid or other bodily fluid tests for specific biomarkers and brain imaging, and it is often a diagnosis of exclusion for other diseases. We utilized a whole transcriptome sequencing approach to analyze gene expression in AD patients and control subjects blood samples with the goal of developing a novel panel of biomarkers for the disease. Whole blood sample were collected from 50 AD patients and 50 matched controls. AD patients were defined by a clinical diagnosis supported by 3 cognitive tests (MMSE, ADAS, CDR). Healthy donors have an unremarkable clinical history and their scores in the 3 cognitive tests are within normal ranges.

2026-03-11 | GSE248422 | GEO

Transcription profiling of human hippocampus samples from patients with Alzheimers disease of varying severity

Project description:For these data, we analyzed hippocampal gene expression of nine control and 22 AD subjects of varying severity on 31 separate microarrays. We then tested the correlation of each gene's expression with MiniMental Status Examination (MMSE) and neurofibrillary tangle (NFT) scores across all 31 subjects regardless of diagnosis. These tests revealed a major transcriptional response comprising thousands of genes significantly correlated with AD markers. Several hundred of these genes were also correlated with AD markers across only control and incipient AD subjects (MMSE > 20).

2007-08-14 | E-GEOD-1297 | biostudies-arrayexpress

Incipient Alzheimer's Disease: Microarray Correlation Analyses

2004-07-16 | GSE1297 | GEO

Advancing Personalized Medicine in Alzheimer’s Disease: Liquid Biopsy Epigenomics Unveil APOE ε4-Linked Methylation Signatures

Project description:Recent studies show that patients with Alzheimer’s disease (AD) harbor specific methylation marks in the brain that, if accessible, could be used as epigenetic biomarkers. Liquid biopsy enables the study of circulating cell-free DNA (cfDNA) fragments originated from dead cells, including neurons affected by neurodegenerative processes. Here, we isolated and epigenetically characterized plasma cfDNA from 35 patients with AD and 35 cognitively healthy controls by using the Infinium® MethylationEPIC BeadChip array. Bioinformatics analysis was performed to identify differential methylation positions (DMPs) and regions (DMRs), including APOE ε4 genotype stratified analysis. Plasma pTau181 (Simoa) and cerebrospinal fluid (CSF) core biomarkers (Fujirebio) were also measured and correlated with differential methylation marks. Validation was performed with bisulfite pyrosequencing and bisulfite cloning sequencing. Epigenome-wide cfDNA analysis identified 102 DMPs associated with AD status. Most DMPs correlated with clinical cognitive and functional tests including 60% for Mini-Mental State Examination (MMSE) and 80% for Global Deterioration Scale (GDS), and with AD blood and CSF biomarkers. In silico functional analysis connected 30 DMPs to neurological processes, identifying key regulators such as SPTBN4 and APOE genes. Several DMRs were annotated to genes previously reported to harbor epigenetic brain changes in AD (HKR1, ZNF154, HOXA5, TRIM40, ATG16L2, ADAMST2) and were linked to APOE ε4 genotypes. Notably, a DMR in the HKR1 gene, previously shown to be hypermethylated in the AD hippocampus, was validated in cfDNA from an orthogonal perspective. These results support the feasibility of studying cfDNA to identify potential epigenetic biomarkers in AD. Thus, liquid biopsy could improve non-invasive AD diagnosis and aid personalized medicine by detecting epigenetic brain markers in blood.

2025-11-26 | GSE311578 | GEO

Predictive potential of circulating Ube2h mRNA as an E2 ubiquitin-conjugating enzyme for diagnosis or treatment of Alzheimer’s disease

Project description:Neurodegenerative disorders are status in which neuronal cell death, miscommunications between synapse, and abnormal accumulation of proteins in the brain. Alzheimer’s disease (AD) is one of the age-related disorders which is most common degenerative disorders today, and strongly involved memory consolidation and cognitive in the brain. Amyloid-β and tau proteins are trigger for AD pathogenesis, and usually use for AD candidate biomarkers in the clinical research. Especially, clinical exam, brain imaging and molecular biological methods are being used to diagnosis for AD. Genome-wide association study (GWAS) is new biomedical method, and use contribute to understanding of many human diseases included brain diseases. Here, we identified ubiquitin conjugating enzyme E2 (Ube2) gene expression in the neuron through GWAS. The subfamilies of Ube2 genetic expression and inborn errors affect ubiquitin proteasome system (UPS) leading to protein degradation in the brain. We found that only Ube2h mRNA transcription was significantly increased in the blood from AD, however we did not find change of Ube2 subfamily genes expression in the blood and brain tissue. These data may provide information of diagnosis or clinical approach, and suggest that cell-free circulating Ube2h mRNA is novel potential biomarker for AD.

2020-12-31 | GSE147792 | GEO

DIA analysis from a large scale patient cohort for Cerebrospinal Fluid Biomarker Discovery in Alzheimer Disease

Project description:Diagnosis of Alzheimer disease (AD) primarily relies on cognitive assessments combined with imaging and cerebrospinal fluid (CSF) biomarkers of amyloid and tau proteins. These biomarkers correlate well with levels of neuropathology, but may be inadequate predictors of cognitive trajectory or treatment response to novel therapeutics. Analysis of larger sets of biomarkers together could improve the diagnosis and prognosis of AD, examine the interaction with and differentiate between comorbid pathophysiologies, and measure treatment efficacy. Here, we report data from a Data-independent Acquisition (DIA) analysis used to simultaneously quantify hundreds of proteins in a large-scale patient cohort from a neurology clinic, all of whom had clinical indication for diagnostic lumbar puncture. We aim to define markers that can stratify and diagnose AD in this clinically-complex cohort. Samples from 408 patients were collected from the clinic according to standardized collection and processing protocols. Samples were prepared in 21 different batches of 24 (23 samples plus one common pool) and analyzed by LC-MS/MS on an Orbitrap Fusion using a DIA method with non-overlapping 25m/z windows from 400-1000 m/z, with a resolution of 120K for MS1 and 60K for MS2. Each sample was injected in duplicate with 4 column washes between each sample. All samples from each batch were run sequentially, with multiples days separating each batch.

2023-06-22 | MSV000092241 | MassIVE

Locus Coeruleus noradrenergic axon loss drives olfactory dysfunction in Alzheimer's disease

Project description:Alzheimer's disease (AD) often begins with non-cognitive symptoms such as olfactory deficits, which can predict later cognitive decline, though the mechanisms remain unclear. Pathologically, the brainstem locus coeruleus (LC), the main source of the neurotransmitter noradrenalin (NA) modulating olfactory information processing is affected ealy. Here we show early and distinct loss of noradrenergic input to the olfactory bulb (OB) coinciding with impaired olfaction in an AD mouse model, before appearance of amyloid plaques. Mechanistically, OB microglia recognize and phagocytose LC axons. Reducing phagocytosis genetically preserves LC axons and olfaction. Importantly, patients with prodromal AD display elevated TSPO-PET signals in the OB, similarly to AppNL-G-F mice. We further confirm early LC axon degeneration in post-mortem OBs in patients with early AD. Our findings reveal a mechanism linking early LC damage to hyposmia in AD, suggesting olfactory testing and neurocircuit imaging for early diagnosis and enable timely therapeutic intervention for Alzheimer's disease.

2025-07-21 | GSE302245 | GEO

Molecular Signatures Underlying Selective Regional Vulnerability to Alzheimer's Disease

Project description:Alzheimer's disease (AD) is the most common form of dementia, characterized by progressive cognitive impairment and neurodegeneration as a result of abnormal neuronal loss. To elucidate the molecular systems associated with AD, we characterized the gene expression changes associated with multiple clinical and neuropathological traits in 1,053 postmortem brain samples across 19 brain regions from 125 persons dying with varying severities of dementia and variable AD-neuropathology severities. 125 human brains were accessed from the Mount Sinai/JJ Peters VA Medical Center Brain Bank (MSBB). This brain resource was assembled after applying stringent inclusion/exclusion criteria and represents the full spectrum of clinical and neuropathological disease severity in the absence of discernable non-AD neuropathology. RNA samples from 19 brain regions isolated from the 125 MSBB specimens were collected and profiled using Affymetrix Genechip microarrays. There were 50 to 60 subjects per brain region with varying degrees of AD pathological abnormalities.

2016-08-19 | E-GEOD-84422 | biostudies-arrayexpress

Scanning ultrasound-mediated memory and functional improvements do not require amyloid-β reduction

Project description:A prevalent view in treating age-dependent disorders including Alzheimer’s disease (AD) is that the underlying amyloid plaque pathology must be targeted for cognitive improvements. In contrast, we report here that repeated scanning ultrasound (SUS) treatment at 1 MHz frequency can ameliorate memory deficits in the APP23 mouse model of AD without reducing amyloid-β (Aβ) burden. Different from previous studies that had shown Aβ clearance as a consequence of blood-brain barrier (BBB) opening, here, the BBB was not opened as no microbubbles were used. Quantitative proteomics and functional magnetic resonance imaging revealed that ultrasound induced long-lasting functional changes that correlate with the improvement in memory. Intriguingly, the treatment was more effective at a higher frequency (1MHz) than at a frequency within the range currently explored in clinical trials in AD patients (286 kHz). Together, our data suggest frequency-dependent bio-effects of ultrasound and a dissociation of cognitive improvement and Aβ clearance, with important implications for the design of trials for AD therapies.

2024-03-19 | PXD050248 | Pride

A blood miRNA signature associates with sporadic Creutzfeldt-Jakob disease diagnosis

Project description:Sporadic Creutzfeldt-Jakob disease (sCJD) presents as a rapidly progressive dementia which is usually fatal within six months. No clinical blood tests are currently available for diagnosis or disease monitoring. Here, we profiled blood microRNA (miRNA) expression in sCJD. Small RNA-sequencing of 57 sCJD patients and 48 healthy controls revealed differential expression of hsa-let-7i-5p, hsa-miR-16-5p, hsa-miR-93-5p and hsa-miR-106b-3p. Downregulation of hsa-let-7i-5p, hsa-miR-16-5p and hsa-miR-93-5p replicated in an independent cohort using quantitative PCR, with concomitant upregulation of four of their mRNA targets. Absence of correlation in cross-sectional analysis with clinical phenotypes paralleled the lack of association between rate of decline in miRNA expression and rate of disease progression in a longitudinal cohort of 50 samples from 21 sCJD patients. Finally, the miRNA signature showed a high level of accuracy in discriminating sCJD from Alzheimer’s disease (AD). These findings highlight novel molecular alterations in the periphery in sCJD which can provide information about differential diagnosis and improve mechanistic understanding of human prion diseases.

2020-01-13 | GSE140069 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data